Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference

New clinical data reported on ppFEV1 measurement taken after washout of alidornase alfa demonstrates meaningful decrease in efficacy parameters once treatment with alidornase alfa stopped further supporting alidornase alfa clinical efficacy alidornase alfa effect on lung function improvement-mean absolute change in ppFEV1 ... 

Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility

Multi-product facility to support the potential manufacturing of both pegunigalsidase alfa and taliglucerase alfa on a commercial scale CARMIEL, Israel, June 01, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that a Supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) has been approved by the FDA.  Approval of the sNDA allows the Company to convert its manufacturing facility in Carmiel, Israel, fr... 

Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference

CARMIEL, Israel, May 25, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on June 7 at 9:00 a.m. ... 
All News